Provided by Tiger Fintech (Singapore) Pte. Ltd.

Charles River Laboratories

163.36
+13.579.06%
Post-market: 162.60-0.7600-0.47%17:41 EDT
Volume:1.88M
Turnover:307.17M
Market Cap:8.02B
PE:-264.28
High:167.83
Open:157.42
Low:155.48
Close:149.79
Loading ...

TRVI Stock Soars on Meeting Primary Goal in Chronic Cough Study

Zacks
·
11 Mar

Charles River Laboratories to Present at Barclays Global Healthcare Conference

Business Wire
·
11 Mar

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress

Business Wire
·
08 Mar

Charles River Laboratories International Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
06 Mar

Spotting Winners: Charles River Laboratories (NYSE:CRL) And Drug Development Inputs & Services Stocks In Q4

StockStory
·
05 Mar

New Tengah and Seletar MRT lines being studied, could be operational from 2040s

CNA
·
05 Mar

Charles River Laboratories Shares Rise After Citigroup Upgrade

MT Newswires Live
·
05 Mar

Charles River Laboratories International Inc : Citigroup Raises Target Price to $175 From $155

THOMSON REUTERS
·
04 Mar

Charles River Labs Raised to Neutral From Sell by Citigroup

Dow Jones
·
04 Mar

Citigroup Upgrades Charles River Laboratories International to Neutral From Sell, Adjusts Price Target to $175 From $155

MT Newswires Live
·
04 Mar

Charles River upgraded to Neutral from Sell at Citi

TIPRANKS
·
04 Mar

Charles River Laboratories International Inc. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
04 Mar

Charles River upgraded to Neutral from Sell at Redburn Atlantic

TIPRANKS
·
03 Mar

Redburn Atlantic Upgrades Charles River Laboratories International to Neutral From Sell, Adjusts PT to $188 From $171

MT Newswires Live
·
03 Mar

Bell Global Equities Sold Charles River Laboratories International (CRL) Due To Its Potential For On-going Risk To Earnings

Insider Monkey
·
28 Feb

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

GlobeNewswire
·
28 Feb

Charles River Laboratories International Inc. Stock Underperforms Thursday When Compared To Competitors

Dow Jones
·
28 Feb

Fibrobiologics and Charles River Announce Completion and Release of Cywc628 Master Cell Bank for the Manufacturing of Fibroblast Cell-Based Wound Healing Therapeutic

THOMSON REUTERS
·
27 Feb

Charles River Laboratories International's (NYSE:CRL) Soft Earnings Don't Show The Whole Picture

Simply Wall St.
·
26 Feb

Charles River announces CAR T-cells agreement with Singapore General Hospital

TIPRANKS
·
25 Feb